Insilico Medicine (HKEX: 3696) reported first-half 2026 revenue of US$106.3 million, up 287.2% year over year, with a gross profit margin of 90.3%, net profit of US$35.54 million, adjusted net profit of US$51.23 million and positive operating cash flow. Cash and investments totaled US$584.8 million as of June 30, 2026, marking the company’s first interim report with full profitability since its December 30, 2025, listing on the Main Board of the Hong Kong Stock Exchange. Drug discovery and pipeline development revenue exceeded US$103.1 million, driven by upfront and milestone payments, while software solutions revenue rose to US$2.70 million. The company said transactions announced in 2026 had an aggregate contract value of approximately US$7.3 billion as of the Latest Practicable Date, including agreements with Servier, Lilly, Hygtia Therapeutics, Qilu Pharmaceutical, CMS, Tenacia Biotechnology, SK Biopharmaceuticals and Takeda Pharmaceutical. Insilico also announced 9 pre-clinical candidate nominations and reported 8 clinical advancements since the start of 2026, including progress for Rentosertib, Garutadustat, ISM8969/HT-001, ISM9682 (MEN2501) and ISM6331. Its Pharma.AI platform expanded through AI agents, foundation-model training and evaluation, autonomous laboratories and cloud collaborations, while the company gained analyst coverage, index inclusions and industry recognition. Insilico said it will continue advancing clinical and early-stage programs, developing AI models and upgrading automated-laboratory infrastructure.